Oncology

Oncology

Lilly's Oncology Momentum Soars: Olomorasib Gains Breakthrough Status, Jaypirca Achieves Landmark Clinical Successes

Eli Lilly and Company (NYSE: LLY) is making significant waves in the oncology landscape with a series of major announcements concerning two of its innovative cancer therapies: Olomorasib and Jaypirca (pirtobrutinib). Olomorasib recently secured a coveted Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug Administration (FDA) for